Galinpepimut-S (GPS)

Presentations

Publications

  • Zauderer MG, et al. A randomized phase II trial of adjuvant galinpepimut-S, WT-1 analogue peptide vaccine, after multimodality therapy for patients with malignant pleural mesothelioma. Clin Cancer Res. 2017;23:7483-9; doi: https://doi.org/10.1158/1078-0432.ccr-17-2169
  • Brayer J, et al. WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides. Am J Hematol. 2015;90:602-7; doi: https://doi.org/10.1002/ajh.24014
  • Maslak PG, et al. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood. 2010;116:171-9; doi: https://doi.org/10.1182/blood-2009-10-250993
  • Krug LM, et al. WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer. Cancer Immunol Immunother. 2010;59: 1467-79; doi: https://doi.org/10.1007/s00262-010-0871-8
  • May RJ, et al. Peptide epitopes from the Wilms’ tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells. Clin Cancer Res. 2007;13:4547-55; doi: https://doi.org/10.1158/1078-0432.ccr-07-0708
  • Pinilla-Ibarz J, et al. Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein. Leukemia. 2006;20:2025-33; doi: https://doi.org/10.1038/sj.leu.2404380